Vitamin E study
This article was originally published in The Tan Sheet
Executive Summary
A National Institutes of Health-funded study establishes a framework for future studies assessing the ability of therapeutic agents to suppress oxidative stress in humans by providing information on the dosage of vitamin E that decreases systemic oxidant stress in vivo in humans, according to the authors of the study recently published in Free Radical Biology & Medicine. The trial included a time-course study on participants supplemented with 3,200 IU/day of vitamin E for 20 weeks and found maximum suppression of plasma F2-isoprostane concentrations did not occur until 16 weeks of supplementation, L. Jackson Roberts II, Vanderbilt University Pharmacology and Medicine departments, et al., say. Researchers also conducted a dose-ranging study in which participants were supplemented with various doses of vitamin E every day for 16 weeks, and found a linear trend between the dosage of vitamin E and percentage reduction in plasma F2-isoprostane concentrations...
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.